Pradana Andika, Sari Dina Keumala, Rusda Muhammad, Tarigan Amira Permatasari, Wiyono Wiwien Heru, Soeroso Noni Novisari, Eyanoer Putri Chairani, Amin Mustafa Mahmud
Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.
Rep Biochem Mol Biol. 2024 Oct;13(3):322-328. doi: 10.61186/rbmb.13.3.322.
Systemic inflammation is one of hallmarks in chronic obstructive pulmonary disease (COPD), contributing to high morbidity and mortality due to elevated levels of interleukin-6 (IL-6) and reduced level of interleukin-10 (IL-10). Probiotics have the potential to reduce systemic inflammation through the gut-lung axis. This study aims to assess the effect of probiotics compared with an inhaled bronchodilator on serum IL-6 and IL-10 levels in mice model of COPD.
This was an in vivo experimental study with a post-test only control group design. Thirty C57BL/6 mice were randomized into five groups; NC (healthy mice), PC (COPD induced mice); T1 (COPD mice treated with a bronchodilator), T2 (COPD mice treated with probiotics) and T3 (COPD mice treated with both a bronchodilator and probiotics). COPD was induced for 12 weeks, followed by a 6-week treatment period. After completing the treatment, serum IL-6 and IL-10 levels were measured using the enzyme-linked immunosorbent assay (ELISA).
The IL-6 levels in T2 group were reduced to levels comparable to the negative control group (13.5 vs 12.0 pg/ml respectively, p=0.84). The IL-10 levels were higher in T2 group compared to T1 group, however; this difference was not statistically significant (181.4 vs 155.0 respectively, p>0.05).
In mice model of COPD, probiotics have been shown to lower IL-6 levels and, to a lesser extent, increased IL-10. As a result, probiotics may have a protective effect against systemic inflammation.
全身炎症是慢性阻塞性肺疾病（COPD）的标志性特征之一，由于白细胞介素-6（IL-6）水平升高和白细胞介素-10（IL-10）水平降低，导致高发病率和死亡率。益生菌有可能通过肠-肺轴减轻全身炎症。本研究旨在评估与吸入性支气管扩张剂相比，益生菌对COPD小鼠模型血清IL-6和IL-10水平的影响。
这是一项体内实验研究，采用仅设后测对照组的设计。30只C57BL/6小鼠随机分为五组；NC组（健康小鼠）、PC组（诱导COPD的小鼠）；T1组（用支气管扩张剂治疗的COPD小鼠）、T2组（用益生菌治疗的COPD小鼠）和T3组（用支气管扩张剂和益生菌治疗的COPD小鼠）。诱导COPD 12周，随后进行6周的治疗期。治疗结束后，采用酶联免疫吸附测定（ELISA）法检测血清IL-6和IL-10水平。
T2组的IL-6水平降至与阴性对照组相当的水平（分别为13.5 pg/ml和12.0 pg/ml，p = 0.84）。然而，T2组的IL-10水平高于T1组；这种差异无统计学意义（分别为181.4和155.0，p>0.05）。
在COPD小鼠模型中，已证明益生菌可降低IL-6水平，并在较小程度上提高IL-10水平。因此，益生菌可能对全身炎症具有保护作用。
